Lung adenocarcinoma

This study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…

This study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …

This study looks at whether giving targeted drugs called ROS1 inhibitors before surgery can help people with a rare form of lung cancer. The drugs, entrectinib or crizotinib, are designed to attack cancer cells with a specific genetic change. Researchers will check how much the t…

This study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation helps people with stage III non-small cell lung cancer live longer without their cancer getting worse. About 170 adults with advanced lung cancer took part. The goal …

This phase 2 trial tested two drugs, osimertinib and gefitinib, in 156 people with advanced EGFR-mutant lung cancer. The goal was to see if using blood tests (liquid biopsies) to detect genetic changes could help decide when to switch treatments, compared to standard scans. The s…

This study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…

This study tested a new two-drug combination (bemcentinib plus pembrolizumab) in 99 adults with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or stop them from growing. Participants received both drugs by mouth or I…

This study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…

This study investigates whether a simple blood test (liquid biopsy) can track how advanced non-small cell lung cancer changes during immunotherapy or targeted therapy. Researchers will analyze tumor DNA circulating in the blood to see if it can predict treatment response and dete…

This study enrolled 200 adults with lung adenocarcinoma that has spread to the bones. Researchers took bone biopsies, scans, and blood tests to measure bone and metabolic markers. The goal is to see if these markers are linked to how long patients live. This is an observational s…